


Technology/ Title	DBPR22998/ A QPCTL (IsoQC) Inhibitor Targeting CD47-SIRP α Axis- Novel innate immune checkpoint inhibitor	
Subtitle		
Technology Type	<input type="checkbox"/> Biotechnology	<input type="checkbox"/> Device/Diagnostics
	<input type="checkbox"/> Pharmaceutical	<input checked="" type="checkbox"/> Others: <u>Oncology/Cancer</u> <u>Immunotherapy</u>
Contact Person	Name: Cindy Hsieh	Title: Manager
	Telephone(work): +886-37246166- 33209	Mobile:
	Email: wenchuan@nhri.edu.tw	
Link	https://ibpr.nhri.edu.tw/zhtw/wp-content/uploads/2023/06/NCR-of-isoQC-DBPR22998-JY-edit-5-25-2023.pdf	
Technology Description	<p>Introduction:</p> <p>CD47-SIRPα "Do-not-eat- me" signaling axis is myeloid-specific innate immune checkpoint. Cancer cells express CD47 on the cell surface enable them to evade detection by the innate immune system and thus avoid destruction by macrophages.</p> <p><u>Key Features</u></p> <ul style="list-style-type: none"> • An orally bioavailable small molecule isoQC (QPCTL) inhibitor modulating CD47-SIRPα "Do not eat me" cancer immune checkpoint activities • Target post translational modification process of CD47 protein synthesis • Opportunity for combination with anti-tumor antibody therapeutics and immune checkpoint inhibitors (ICIs) <p><u>Pharmaceutical Development</u></p> <ul style="list-style-type: none"> • Crystalline form identified; physicochemical properties/pre-formulation/formulation evaluation underway <p><u>Market Positioning</u></p> <ul style="list-style-type: none"> • Anti-CD47 monoclonal antibodies are the most extensively studies for cancer immunotherapy. As opposed to antibody approaches in clinical development, our small molecule isoQC (QPCTL) inhibitor DBPR22998 is a best-in-class and innovative therapeutic approach for boosting the efficiency of cancer immunotherapy. 	

Intellectual Property	US/PCT patents
Key Publications	NA
Business Opportunity	Technology transfer; Co-development

**CD47-SIRP α Signaling:
Mask Macrophage to See Cancer Cells**



**DBPR22998: A potent IsoQC (QPCTL) Inhibitor
Targeting CD47-SIRP α "Don't Eat Me" Signal**

